Evidence map›Paper›PMID 32009788›Full record

ArticleNeuropsychiatric disease and treatment2019

Profile Of Patients With Advanced Parkinson's disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients.

József Attila Szász, Viorelia Adelina Constantin, Károly Orbán-Kis, Attila Rácz, Ligia Ariana Bancu, Dan Georgescu, János Szederjesi, István Mihály, Ana-Mária Fárr, Krisztina Kelemen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychiatric disease and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

József Attila Szász *University of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.ORCID 0000-0003-1675-036X
Viorelia Adelina Constantin *2nd Clinic of Neurology, Târgu Mures County Emergency Clinical Hospital, Târgu Mures, Romania.ORCID 0000-0002-1242-3751
Károly Orbán-KisUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.
Attila Rácz2nd Clinic of Psychiatry, Târgu Mures County Emergency Clinical Hospital, Târgu Mures, Romania.
Ligia Ariana BancuUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.
Dan GeorgescuUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.
János SzederjesiUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.
István MihályUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.
Ana-Mária FárrUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.
Krisztina KelemenUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.
Tamás VajdaDepartment of Computer Science, Faculty of Technical and Human Sciences, Sapientia Hungarian University of Transylvania, Târgu Mureș, Romania.
Szabolcs SzatmáriUniversity of Medicine and Pharmacy of Târgu Mures, Târgu Mureş, Romania.ORCID 0000-0001-8197-3231

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is insufficient data in the literature regarding the real-life, daily clinical practice evaluation of patients with advanced Parkinson's disease (APD). We are not sure what is the upper limit of dopaminergic medication, especially the levodopa (LD) dosage, and how it is influenced by access and suitability to the various add-on and device-aided therapies (DAT).

objectiveThis retrospective study explored the profile of APD patients that were considered and systematically evaluated regarding the suitability for DAT.

methodsWe analyzed the data from 311 consecutive patients with APD hospitalized between 2011 and 2017 that 1) described at least 2 hrs/day off periods divided into at least two instances/day (except early morning akinesia), 2) were in stage 3 or above on the Hoehn and Yahr scale, 3) were with or without dyskinesia, and 4) received at least four levodopa doses/day combined with adjuvant therapy.

resultsOf the 311 patients enrolled initially, 286 patients showed up for the second visit, of which in 125 cases we assessed that DAT would be necessary. Finally, 107 patients were tested in our clinic to confirm the efficacy of LCIG. Patients selected for DAT had significantly longer off periods, more frequent dyskinesia, early morning akinesia, and freezing despite having significantly higher LD doses than those with an improved conservative therapy.

conclusionPatients with APD can have a variety of symptoms, and because symptoms and therapeutical efficacy can be manifested in many different combinations, it is not possible to decide using a single, rigid set of criteria which APD patient is eligible for DAT. Nevertheless, treating physicians should refer APD patients to a specialized movement disorder center when patients with an average daily dose of LD of at least 750-1000 mg and maximal complementary therapies present daily motor complications that significantly reduce the quality of life.

Indexed as

advanced Parkinson’s diseaselevodopa-carbidopa intestinal gellevodopa dosesmotor complications

Identifiers

PMID32009788
PMCPMC6859121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.